These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 3741052)

  • 1. [Therapeutic effect of the temporary interruption of treatment of long-term parkinsonian patients: role of the peripheral metabolism of L-DOPA].
    García García B; Hernández Calzadilla C; Barajas García-Talavera F; Fernández Martín F; Pérez de Paz A; Rodríguez Díaz M
    Arch Neurobiol (Madr); 1986; 49(3):145-52. PubMed ID: 3741052
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
    Brannan T; Yahr MD
    Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of parkinson disease with the combination of L-dopa (plus carbidopa) and trazodone].
    Piccinin GL; Piccirilli M; Agostini L
    Clin Ter; 1981 Mar; 96(6):621-6. PubMed ID: 7285527
    [No Abstract]   [Full Text] [Related]  

  • 4. Long term bromocriptine treatment in de novo parkinsonian patients.
    Herskovits E; Yorio A; Leston J
    Medicina (B Aires); 1988; 48(4):345-50. PubMed ID: 3076200
    [No Abstract]   [Full Text] [Related]  

  • 5. [Usefulness of increasing the proportion of carbidopa to levodopa in the long-term treatment of Parkinson's disease].
    Bermejo Pareja F; Martínez-Martín P
    Med Clin (Barc); 1984 Feb; 82(7):305-10. PubMed ID: 6717135
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
    Pahwa R; Koller WC
    Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of parkinsonism by L-dopa and dopa-decarboxylase inhibitor in a single tablet].
    Sarova-Pinhas I; Braham J
    Harefuah; 1974 Sep; 87(5):208-10. PubMed ID: 4435614
    [No Abstract]   [Full Text] [Related]  

  • 8. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure.
    Nyholm D; Lewander T; Johansson A; Lewitt PA; Lundqvist C; Aquilonius SM
    Clin Neuropharmacol; 2008; 31(2):63-73. PubMed ID: 18382177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The combination of L-dopa and carbidopa in therapy of a case of familial juvenile parkinsonism].
    Piccirilli M; Piccinin GL; La Medica A
    Clin Ter; 1981 Feb; 96(3):335-40. PubMed ID: 7307449
    [No Abstract]   [Full Text] [Related]  

  • 10. [A year of treatment with carbidopa and levodopa in Parkinsonian patients].
    Martínez-Lage JM; Marti-Massó JF; Delgado G; Carreray N; Del Amo F
    Rev Clin Esp; 1974 Sep; 134(6):535-42. PubMed ID: 4450036
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of complicated Parkinson disease with a solution of levodopa-carbidopa and ascorbic acid].
    Linazasoro G; Gorospe A
    Neurologia; 1995; 10(6):220-3. PubMed ID: 7546811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease.
    Brusa L; Petta F; Pisani A; Moschella V; Iani C; Stanzione P; Miano R; Finazzi-Agrò E
    Neurology; 2007 May; 68(18):1455-9. PubMed ID: 17470746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combined therapy of carbidopa and levodopa in Parkinson's disease].
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):201-4. PubMed ID: 4075908
    [No Abstract]   [Full Text] [Related]  

  • 14. [Biochemical evaluation of the effectiveness of antiparkinson preparations containing L-DOPA].
    Vartanian KZ
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1981; 81(12):1777-81. PubMed ID: 6803476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical experience in switching patients from standard levodopa to a controlled-release levodopa].
    Leiva Santana C; Galvañ Berenguer B; Gómez García J; Cabello López J
    Neurologia; 1996 Jan; 11(1):1-9. PubMed ID: 8714169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The L-dopa test in Parkinson's disease].
    Esteguy M; Bonnet AM; Kefalos J; Lhermitte F; Agid Y
    Rev Neurol (Paris); 1985; 141(5):413-5. PubMed ID: 4048732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
    Admani AK; Verma S; Cordingley GJ; Harris RI
    Pharmatherapeutica; 1985; 4(2):132-40. PubMed ID: 4059292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations.
    Kurlan R; Rubin AJ; Miller C; Rivera-Calimlim L; Clarke A; Shoulson I
    Ann Neurol; 1986 Aug; 20(2):262-5. PubMed ID: 3752968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soft tissue-anchored transcutaneous port attached to an intestinal tube for long-term gastroduodenal infusion of levodopa/carbidopa in Parkinson disease.
    Nyman R; Lundgren D; Nyholm D
    J Vasc Interv Radiol; 2009 Apr; 20(4):500-5. PubMed ID: 19216094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of simultaneous administration of pyridoxine in the combined administration of L-dopa and peripheral decarboxylase inhibitors. Experimental and clinical studies].
    Namba S; Omoto T; Kishikawa H
    No To Shinkei; 1976 Aug; 28(8):815-22. PubMed ID: 829033
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.